STOCK TITAN
  1. Home
  2. Sec-filings
  3. KNSA
  4. [Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Kiniksa COO granted 36,950-share option, RSUs

Kiniksa’s COO received new RSU and option grants and exercised earlier RSUs into Class A shares, with some shares withheld for costs.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) reported that Chief Operating Officer Ross Moat received equity awards and exercised existing awards on September 1, 2026. He was granted 9,250 Restricted Share Units, plus a Share Option for 36,950 Class A Ordinary Shares at an exercise price of $79.28. Several prior RSU grants totaling 8,285 units were exercised into the same number of Class A Ordinary Shares, and 4,007 shares were delivered or withheld to pay the option exercise price or tax liability. The new RSUs and options generally vest over four years starting on September 1, 2026, with 25% vesting on the first anniversary and the remainder in subsequent installments. No Rule 10b5-1 trading plan is reported.

Positive

  • None.

Negative

  • None.
Insider Moat Ross
Role CHIEF OPERATING OFFICER
Type Security Shares Price Value
Grant/Award Restricted Share Unit F1, F2 9,250 $0.00 $0.00
Grant/Award Share Option F3 36,950 $0.00 $0.00
Exercise Restricted Share Unit F1, F4 2,457 $0.00 $0.00
Exercise Restricted Share Unit F1, F5 1,740 $0.00 $0.00
Exercise Restricted Share Unit F1, F6 1,611 $0.00 $0.00
Exercise Restricted Share Unit F1, F7 2,477 $0.00 $0.00
Exercise Class A Ordinary Share F1 2,477 -- --
Exercise Class A Ordinary Share F1 1,611 -- --
Exercise Class A Ordinary Share F1 1,740 -- --
Exercise Class A Ordinary Share F1 2,457 -- --
Exercise Price or Tax Liability Class A Ordinary Share 4,007 $79.28 $318K
Holdings After Transaction: Restricted Share Unit — 21,713 contracts (Direct); Share Option — 36,950 contracts (Direct); Class A Ordinary Share — 16,307 shares (Direct)
Footnotes (7)
  1. F1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
  2. F2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
  3. F3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
  4. F4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
  5. F5. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
  6. F6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
  7. F7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
RSUs granted 9,250 units Restricted Share Units granted to COO on September 1, 2026
Options granted 36,950 shares Share Option for Class A Ordinary Shares granted on September 1, 2026
Option exercise price $79.28 per share Exercise price for the 36,950-share option grant
RSUs exercised 8,285 units Previously granted RSUs exercised into Class A Ordinary Shares on September 1, 2026
Shares withheld for costs 4,007 shares Class A Ordinary Shares delivered or withheld to pay exercise price or tax liability at $79.28 per share
RSU vesting period 4 years RSUs vest 25% on each yearly anniversary of September 1, 2026
Restricted Share Unit financial
"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share"
A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.
Share Option financial
"The option vests and becomes exercisable as to 25% of the total grant"
Class A Ordinary Share financial
"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share"
A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.
exercise price financial
"Payment of exercise price or tax liability by delivering or withholding securities"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting commencement date financial
"The vesting commencement date is September 1, 2026."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

What equity awards did KNSA grant to its COO Ross Moat on September 1, 2026?
On September 1, 2026, Ross Moat received 9,250 Restricted Share Units and a Share Option for 36,950 Class A Ordinary Shares with an exercise price of $79.28 per share as part of his equity compensation.

How many KNSA RSUs did the COO exercise into Class A Ordinary Shares?
On September 1, 2026, Ross Moat exercised previously granted RSUs covering 8,285 units, converting them into 8,285 Class A Ordinary Shares of Kiniksa Pharmaceuticals International, plc.

What is the vesting schedule for the new KNSA RSUs and options granted to the COO?
The new RSUs and options vest over four years. For the RSUs, 25% vest on each yearly anniversary of the September 1, 2026 grant date. The option vests 25% on the first anniversary of the vesting commencement date, then in 36 equal monthly installments.

Were any KNSA shares withheld to cover exercise price or taxes for the COO’s transactions?
Yes. On September 1, 2026, 4,007 Class A Ordinary Shares of Kiniksa were delivered or withheld at $79.28 per share to pay the option exercise price or tax liability related to the equity award transactions.

Was a Rule 10b5-1 trading plan used for these KNSA insider transactions?
No. The filing indicates the Rule 10b5-1 checkbox is not selected, meaning these September 1, 2026 equity award and related share transactions were not reported as made under a Rule 10b5-1 trading plan.

What underlying security do KNSA RSUs represent for the COO’s awards?
Each of the COO’s Restricted Share Units represents a contingent right to receive one Class A Ordinary Share of Kiniksa Pharmaceuticals International, plc upon vesting and settlement, according to the footnotes in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Moat Ross
(Last)(First)(Middle)
C/O KINIKSA PHARMACEUTICALS INT'L
105 PICCADILLY, SECOND FLOOR
(Street)
LONDONW1J 7NJ
(City)(State)(Zip)
UNITED KINGDOM
(Country)		2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF OPERATING OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Ordinary Share09/01/2026M2,477A(1)14,506D
Class A Ordinary Share09/01/2026M1,611A(1)16,117D
Class A Ordinary Share09/01/2026M1,740A(1)17,857D
Class A Ordinary Share09/01/2026M2,457A(1)20,314D
Class A Ordinary Share09/01/2026F4,007D$79.2816,307D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Share Unit(1)09/01/2026A9,250 (2) (2)Class A Ordinary Share9,250$09,250D
Share Option$79.2809/01/2026A36,950 (3)08/31/2036Class A Ordinary Share36,950$036,950D
Restricted Share Unit(1)09/01/2026M2,457 (4) (4)Class A Ordinary Share2,457$07,371D
Restricted Share Unit(1)09/01/2026M1,740 (5) (5)Class A Ordinary Share1,740$03,481D
Restricted Share Unit(1)09/01/2026M1,611 (6) (6)Class A Ordinary Share1,611$01,611D
Restricted Share Unit(1)09/01/2026M2,477 (7) (7)Class A Ordinary Share2,477$00D
Explanation of Responses:
1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
5. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
/s/ Douglas Barry, Attorney-in-Fact09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR